转甲状腺素蛋白淀粉样心肌病二尖瓣反流的定义与预后:多中心国际队列研究
该多中心国际队列研究纳入1101例新诊断转甲状腺素蛋白淀粉样心肌病患者,通过标准化超声心动图评估二尖瓣反流指标并推导疾病特异性风险阈值。结果显示定量二尖瓣反流阈值显著低于现行指南截断值,基于风险的复合分级方案能更好预测死亡和心衰住院,更贴合限制性低血流病理生理。
要点
- 转甲状腺素蛋白淀粉样心肌病中二尖瓣反流定量阈值应低于现行指南截断值。
- 基于风险的复合分级方案较指南分级能识别更多重度二尖瓣反流并改善预后判别。
- 复合分级方案在多变量调整后仍独立预测死亡和心衰住院。
核心结论
- 转甲状腺素蛋白淀粉样心肌病的定量二尖瓣反流阈值显著低于现行指南截断值,基于风险的复合分级方案改善死亡和心衰住院预测。
研究设计与样本
- 多中心队列研究,纳入8个中心4个国家1101例新诊断转甲状腺素蛋白淀粉样心肌病患者(推导队列n=722,验证队列n=379),行标准化超声心动图盲法核心实验室分析。
主要发现
- 中位随访24.9个月(四分位距12.0-42.0),314例(28.5%)死亡,244例(22.2%)发生心衰住院。
- 所有二尖瓣反流指标均独立预测死亡和心衰住院(均P<0.05)。
- 样条分析推导的中风险阈值为缩流颈宽度≥3.0 mm、有效反流口面积≥0.10 cm2、反流量≥15 mL、反流分数≥20%;高风险阈值为有效反流口面积>0.25 cm2、反流量>38 mL、反流分数>35%。
- 复合分级方案将21%患者归为重度二尖瓣反流,高于指南分级的约12%-13%,且在推导和验证队列中12和24个月临床结局判别均更优。
- 多变量调整后,仅复合分级方案对死亡(风险比1.20 [1.07-1.36])和心衰住院(风险比1.21 [1.05-1.38])保持强预测。
关键数值与推荐
- 中风险:缩流颈宽度≥3.0 mm、有效反流口面积≥0.10 cm2、反流量≥15 mL、反流分数≥20%。
- 高风险:有效反流口面积>0.25 cm2、反流量>38 mL、反流分数>35%。
临床怎么用
- 在转甲状腺素蛋白淀粉样心肌病中应采用疾病特异性定量二尖瓣反流阈值评估严重程度。
- 复合分级方案可改善死亡和心衰住院风险分层,优于现行指南分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performance with guideline definitions. METHODS: In a multicenter cohort study (8 centers, 4 countries), 1101 patients with newly diagnosed transthyretin amyloid cardiomyopathy (derivation, n=722; validation, n=379) underwent standardized echocardiography with blinded core laboratory analysis, including MR measures (vena contracta width, effective regurgitant orifice area, regurgitant volume, and regurgitant fraction). All-cause mortality and time to first heart failure hospitalization (HFH) served as end points. Prognostic thresholds were derived from spline analysis, validated externally, and compared with American Heart Association/American College of Cardiology, European Society of Cardiology/European Association for Cardiothoracic Surgery, and American Society of Echocardiography definitions. RESULTS: During a median follow-up of 24.9 months (interquartile range, 12.0-42.0), 314 patients (28.5%) died and 244 (22.2%) experienced HFH. All MR metrics independently predicted mortality and HFH (all P<0.05). Spline-derived thresholds identified intermediate risk at vena contracta width ≥3.0 mm, effective regurgitant orifice area ≥0.10 cm2, regurgitant volume ≥15 mL, and regurgitant fraction ≥20% and high risk at effective regurgitant orifice area >0.25 cm2, regurgitant volume >38 mL, and regurgitant fraction >35%. Compared with guideline grading (≈12%-13%), the composite MR grading scheme classified a significantly higher proportion (21%) as severe MR and provided superior discrimination for clinical outcomes at 12 and 24 months in both the derivation and validation cohort. After multivariable adjustment, only the composite MR grading scheme remained strongly predictive for both mortality (hazard ratio, 1.20 [1.07-1.36]) and HFH (hazard ratio, 1.21 [1.05-1.38]). CONCLUSIONS: Quantitative MR thresholds in transthyretin amyloid cardiomyopathy are substantially lower than current guideline cutoffs. A validated, risk-based composite MR grading scheme improves prediction of both mortality and HFH, better reflecting the restrictive low-flow pathophysiology of transthyretin amyloid cardiomyopathy and supporting disease-specific MR grading. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06836011.
引用
- Hauptmann L, Kronberger C, Schwarting SK, et al. Definition and Prognosis of Mitral Regurgitation in Transthyretin Amyloid Cardiomyopathy: A Multicenter International Cohort Study. Circulation. 2026. PMID: 42866868. doi:10.1161/CIRCULATIONAHA.125.079085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。